World Lung Cancer Day 2026: Why Non-Smokers Get Lung Cancer Too and What to Watch For

If you have never smoked, you probably do not think of yourself as someone at risk for lung cancer. That assumption is understandable. The link between smoking and lung cancer is one of the most established facts in medical science, and decades of public health messaging have rightly reinforced it. But this strong association has also created a dangerous blind spot: lung cancer can affect people who have never smoked too.

This blind spot matters because it can delay diagnosis. A non-smoker with a persistent cough may blame pollution, allergy, acid reflux, or a lingering infection. Breathlessness may be linked to age, stress, or poor stamina. Chest discomfort may be dismissed as acidity or muscle strain. In many cases, these explanations may be correct, but when symptoms persist, worsen, or keep coming back, they need medical attention.

For non-smokers, the absence of a smoking history can sometimes make lung cancer feel impossible, both to the patient and, at times, even during early clinical evaluation. That is why awareness needs to go beyond tobacco alone. Smoking remains the most important risk factor, but it is not the only one.

World Lung Cancer Day 2026 is a reminder to look beyond the smoking stereotype and recognise that timely evaluation matters for everyone. In this blog, we’ll address a question that is often missed in lung cancer awareness: why can non-smokers develop lung cancer, what symptoms should they watch for, and when should they seek specialist care?

What is World Lung Cancer Day?

World Lung Cancer Day is observed every year on 1 August to raise awareness about lung cancer, support people affected by the disease, reduce stigma, and encourage timely diagnosis and treatment.

The day brings attention to an important public health message: lung cancer is serious, common, and often diagnosed late, but earlier evaluation can change the course of care. Awareness is not only about prevention; it is also about recognising symptoms, understanding risk factors, and ensuring that people receive specialist advice without unnecessary delay.

World Lung Cancer Day is also an opportunity to correct common misconceptions. Smoking remains the strongest known risk factor for lung cancer, but it is not the only one. People who have never smoked can also develop lung cancer due to factors such as air pollution, second-hand smoke, household air pollution, occupational exposure, radon, chronic lung disease, family history, or tumour-related genetic changes.

For this reason, the message of World Lung Cancer Day 2026 is especially relevant to non-smokers. A persistent cough, breathlessness, chest discomfort, hoarseness, unexplained weight loss, coughing up blood, or repeated chest infections should not be dismissed simply because a person has never smoked.

Lung Cancer in India: A Growing Concern

India’s lung cancer pattern needs to be understood in its own context. While tobacco remains a major risk factor, it does not explain the full picture. Indian studies show that a substantial proportion of lung cancer patients have never smoked, which makes it important to look at non-tobacco risk factors more seriously.

Tobacco Remains Important, but It Is Not the Whole Story

Tobacco remains a major driver of lung cancer, and India continues to have a large tobacco-using population. However, lung cancer in India cannot be explained by smoking alone. A large North Indian study cited in the Indian Journal of Medical Research reported that nearly 44% of new lung cancer cases were seen in non-smokers.

This does not mean smoking is no longer important. It means doctors and patients should not rule out lung cancer simply because a person has never smoked. A persistent cough, breathlessness, chest pain, coughing up blood, unexplained weight loss, or repeated chest infections should be evaluated based on symptoms and risk factors, not smoking history alone.

Air Pollution and Other Non-Tobacco Risk Factors

Air pollution is now an important part of the lung cancer discussion, especially in urban and highly polluted regions. Fine particulate matter, especially PM2.5, can enter deep into the lungs and has been linked with lung cancer risk. The International Agency for Research on Cancer, IARC, has classified outdoor air pollution and particulate matter in outdoor air as carcinogenic to humans.

This is especially relevant for India, where many people are exposed to high levels of outdoor air pollution, indoor smoke from biomass fuels, second-hand smoke, and workplace-related pollutants. Recent research has also highlighted that adenocarcinoma, a subtype commonly seen in non-smokers, is increasing globally and may be linked in part to air pollution exposure.

Late Diagnosis and Its Consequences

One of the biggest challenges in India is that lung cancer is often detected late. The Indian Journal of Medical Research notes that most patients in India present with advanced disease, when curative treatment may no longer be possible. Another recent India-focused analysis reported that about 45% of lung cancer cases are diagnosed at a distant stage.

This late diagnosis happens for several reasons. Early symptoms such as cough, breathlessness, fatigue, chest discomfort, or repeated infections may be mistaken for pollution-related irritation, tuberculosis, allergy, asthma, or routine respiratory illness. In non-smokers, the possibility of lung cancer may not be considered early enough.

This is why awareness matters. Lung cancer should not be seen only as a smoker’s disease. In India, timely evaluation is important for anyone with persistent or worsening respiratory symptoms, especially when symptoms do not improve with usual treatment or keep coming back.

Why Non-Smokers Get Lung Cancer

Lung cancer in non-smokers is rarely explained by one single cause. In many cases, it develops because of a combination of environmental exposure, household exposure, workplace risk, inherited susceptibility, previous lung disease, and cancer-related genetic changes. In some patients, no clear risk factor is found.

The important point is this: not smoking lowers the risk of lung cancer, but it does not remove the risk completely. Factors that may increase the risk of lung cancer in non-smokers include:

Air Pollution

Air pollution is an important risk factor for lung cancer, especially in highly polluted urban environments. Fine particulate matter, particularly PM2.5, can enter deep into the lungs and remain there, causing long-term irritation and biological changes in lung tissue.

The International Agency for Research on Cancer, IARC, has classified outdoor air pollution and particulate matter in outdoor air as carcinogenic to humans. More recent genomic research has also shown that PM2.5 exposure in never-smokers is associated with cancer-driving and cancer-promoting mutations in lung tumours.

For people living in cities with high pollution levels, this means lung cancer risk is not limited to smoking history alone. Long-term exposure to polluted air from traffic, industrial emissions, construction dust, fuel burning, and other sources may also contribute to risk.

Indoor Cooking Smoke and Household Air Pollution

Indoor air pollution is another important concern, especially in homes where cooking or heating is done using solid fuels such as wood, charcoal, coal, crop residues, or kerosene in poorly ventilated spaces.

WHO estimates that about 11% of lung cancer deaths in adults are attributable to exposure to carcinogens from household air pollution caused by the use of kerosene or solid fuels for household energy needs. Women may be disproportionately affected because they often spend more time near cooking smoke in many households.

This does not mean every person exposed to cooking smoke will develop lung cancer. But long-term exposure, especially over many years, can increase the risk and should be taken seriously as part of lung cancer prevention and awareness.

Second-Hand Smoke Exposure

Second-hand smoke is a proven lung cancer risk factor. A person who does not smoke may still inhale carcinogens from tobacco smoke at home, at work, or in shared spaces.

This exposure can be especially harmful when it is frequent or long-term, such as living with a smoker for many years or working in an environment where smoking exposure is common. The risk depends on the duration and intensity of exposure.

Radon Gas

Radon is a naturally occurring radioactive gas produced from the breakdown of uranium in soil and rock. It can enter buildings through cracks in floors, walls, or foundations and may accumulate indoors, especially in poorly ventilated spaces.

Radon is an established lung cancer risk factor. Its impact varies by geography, building structure, ventilation, and indoor concentration levels. While radon testing is not commonly discussed in India, it remains an important environmental risk factor in lung cancer science.

Occupational Exposures

Some people develop lung cancer because of long-term exposure to cancer-causing substances at work. These may include asbestos, silica, diesel exhaust, arsenic, chromium, nickel, beryllium, coal dust, and certain industrial chemicals.

Workers in construction, mining, welding, painting, manufacturing, transport, and some chemical industries may have higher exposure depending on their workplace conditions. Protective equipment, ventilation, exposure monitoring, and workplace safety standards are important to reduce risk.

Genetic Mutations and Molecular Drivers

Lung cancer in non-smokers often has a different molecular profile from smoking-related lung cancer. Non-smokers with lung adenocarcinoma are more likely to have certain genetic changes in the tumour, such as EGFR mutations, ALK rearrangements, ROS1 fusions, and other targetable alterations.

This is clinically important because these mutations can influence treatment decisions. In selected patients, targeted therapies may be used to block specific cancer-driving changes and can offer more personalized treatment than conventional chemotherapy alone.

Indian studies have reported EGFR mutations in a significant proportion of lung adenocarcinoma patients, and ALK rearrangements are also seen in a smaller but important group of patients, often among younger patients and non-smokers. This is why molecular testing is an important part of lung cancer diagnosis and treatment planning, especially in advanced non-small cell lung cancer.

Prior Lung Disease

Certain chronic lung conditions may increase lung cancer risk, even in people who have never smoked. These include chronic obstructive pulmonary disease, pulmonary fibrosis, and previous lung infections or scarring, including tuberculosis in some patients.

Long-standing inflammation, repeated injury, or scarring in the lungs may create conditions that increase the chance of abnormal cell changes over time. A history of lung disease does not mean a person will develop lung cancer, but it is relevant when assessing risk and symptoms.

Family History

A family history of lung cancer may also increase risk. This may be due to inherited susceptibility, shared environmental exposure, or a combination of both.

People with a first-degree relative, such as a parent, sibling, or child, who has had lung cancer should mention this to their doctor, especially if they develop persistent respiratory symptoms. Family history alone does not confirm high risk, but it helps doctors understand the person’s overall risk profile.

The Bottom Line

Non-smokers can develop lung cancer because risk is shaped by more than tobacco alone. Air pollution, household smoke, second-hand smoke, radon, workplace exposure, chronic lung disease, family history, and tumour-related genetic changes can all play a role.

This is why persistent symptoms such as cough, breathlessness, chest pain, coughing up blood, unexplained weight loss, hoarseness, or repeated chest infections should not be ignored, even in someone who has never smoked.

Symptoms of Lung Cancer Non-Smokers Should Not Ignore

The difficult part about early lung cancer is that it may not cause obvious symptoms at first. Lung tissue itself has very few pain receptors, which means a tumour can sometimes grow for months without causing discomfort. By the time symptoms become noticeable, the disease may already have progressed beyond the lung.

The symptoms listed below do not always mean lung cancer. Many of them can be caused by infections, allergies, acid reflux, asthma, pollution-related irritation, or other common conditions. However, when these symptoms are persistent, worsening, unexplained, or keep coming back, they should be medically evaluated.

A Persistent Cough

A cough that lasts more than two to three weeks and does not improve with usual treatment for a respiratory infection should not be ignored. It may be dry or productive, may bring up blood-stained sputum, or may feel different from the person’s usual cough pattern.

In a non-smoker, a persistent unexplained cough is especially important because it may be easily dismissed as pollution, allergy, acid reflux, or a lingering viral infection. While these are common causes, a cough that does not settle needs proper evaluation.

Coughing Up Blood

Haemoptysis, which means coughing up blood or blood-streaked sputum, needs prompt medical attention. Even a small amount of blood in coughed-up mucus should not be assumed to be throat irritation without clinical assessment.

Breathlessness on Exertion

New or progressive breathlessness should be taken seriously, especially if routine activities that were previously manageable start causing shortness of breath. This may happen if a tumour narrows an airway, causes fluid collection around the lung (pleural effusion), or affects the lung tissue directly.

Breathlessness that is new, worsening, or not explained by a known heart or lung condition should be evaluated.

Chest Pain or Discomfort

Persistent chest pain, tightness, or a dull ache in the chest, shoulder, or back can sometimes be linked to lung cancer, especially when the pain worsens with deep breathing or coughing. This may occur when a tumour affects the pleura, which is the lining around the lung, or involves the chest wall.

Because chest pain is often attributed to acidity, muscle strain, or posture-related pain, persistent or unexplained discomfort should not be ignored.

Persistent Hoarseness

A change in voice quality or hoarseness that does not improve should be evaluated, especially when there is no obvious cause such as a cold, throat infection, or vocal overuse. In some cases, a tumour in the upper chest or mediastinum can affect the recurrent laryngeal nerve, which controls the voice box.

Recurrent Chest Infections

Repeated chest infections or pneumonia that returns after antibiotic treatment may need further investigation, especially if they affect the same area of the lung on imaging. This can happen when a tumour blocks part of the airway and prevents a section of the lung from clearing properly.

Recurrent pneumonia in the same lobe on chest X-ray should prompt further imaging to rule out an underlying structural cause.

Unexplained Weight Loss and Fatigue

Unintentional weight loss, especially when significant, should not be ignored. When it occurs along with persistent fatigue that does not improve with rest, it may reflect the body’s response to an underlying illness, including cancer.

If unexplained weight loss or fatigue appears along with cough, breathlessness, chest discomfort, or other respiratory symptoms, medical evaluation should not be delayed.

Swelling in the Face or Neck

Swelling in the face, neck, or arms, along with redness or fullness in the face and upper chest, can sometimes occur due to superior vena cava syndrome. This happens when a tumour compresses the large vein that carries blood from the upper body back to the heart.

This is a serious sign and needs urgent medical evaluation.

How is Lung Cancer Diagnosed?

At RGCIRC, evaluation for suspected lung cancer follows a structured, step-by-step approach coordinated by the Thoracic Oncology team. The process may include imaging, tissue diagnosis, staging, and molecular testing to confirm the cancer type and plan the most appropriate treatment.

Chest X-Ray

A chest X-ray is often one of the first tests advised when a patient has persistent cough, breathlessness, chest pain, coughing up blood, or repeated chest infections. It can help detect visible lung abnormalities, fluid around the lung, or a suspicious mass.

However, a chest X-ray may miss small or early-stage lung tumours. A normal chest X-ray does not completely rule out lung cancer if symptoms are persistent or concerning. In such cases, further imaging may be needed.

CT Scan or Low-Dose CT of the Chest

A CT scan of the chest provides more detailed images than a chest X-ray and is much more sensitive in detecting small lung nodules, tumours, lymph node enlargement, or disease spread within the chest.

Low-dose CT, or LDCT, is commonly used for lung cancer screening in high-risk individuals because it uses a lower radiation dose than a standard diagnostic CT scan. For patients who already have symptoms, doctors may advise a diagnostic CT chest, sometimes with contrast, depending on the clinical situation.

Bronchoscopy and EBUS

Bronchoscopy allows doctors to look directly inside the central airways using a thin, flexible tube with a camera. If a tumour is visible or reachable through the airway, a biopsy sample can be taken during the procedure.

Endobronchial ultrasound-guided biopsy, or EBUS, helps doctors sample lymph nodes in the chest, especially mediastinal lymph nodes. This can provide both diagnostic tissue and staging information in a single procedure. EBUS is available at RGCIRC.

CT-Guided Percutaneous Biopsy

Some lung tumours are located in the outer or peripheral parts of the lung and may not be accessible through bronchoscopy. In such cases, a CT-guided percutaneous biopsy may be performed.

During this procedure, imaging guidance is used to pass a needle through the chest wall and collect tissue from the suspicious lung lesion. The sample is then examined to confirm the diagnosis and may also be used for molecular analysis.

Digital PET-CT

Digital PET-CT is used for staging lung cancer. It helps assess whether the cancer has spread to lymph nodes or other parts of the body. This information is important for deciding whether surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of treatments may be suitable.

PET-CT may also be used after treatment to assess response to chemotherapy, targeted therapy, or other cancer treatments. RGCIRC offers Digital PET-CT at both campuses.

Molecular and Biomarker Testing

Once lung cancer is confirmed, molecular and biomarker testing plays a critical role in treatment planning, especially for non-smokers and patients with non-squamous non-small cell lung cancer.

At RGCIRC, molecular profiling may include testing for EGFR mutations, ALK rearrangements, ROS1 fusions, KRAS G12C, MET exon 14 skipping, BRAF V600E, and RET fusions through next-generation sequencing, depending on the case. PD-L1 expression testing may also be performed to assess whether immunotherapy could be suitable.

These results help doctors choose the most appropriate systemic treatment. For some patients, molecular testing can identify targetable alterations that may be treated with precision medicines, forming the foundation of personalized lung cancer care.

How is Lung Cancer Treated?

Lung cancer treatment depends on several factors, including the stage of the disease, the type of lung cancer, the patient’s overall health, lung function, and the molecular profile of the tumour. This molecular profile is especially important in many non-smokers, as their tumours may carry targetable genetic changes.

At RGCIRC, lung cancer cases are reviewed through a Multidisciplinary Tumour Board before treatment begins. This helps the team decide the most appropriate sequence of treatment, which may include surgery, radiation therapy, targeted therapy, immunotherapy, chemotherapy, supportive care, or a combination of these.

Surgery

For early-stage lung cancer in patients who are medically fit for an operation, surgery may offer the best chance of long-term control or cure. The aim is to remove the tumour completely while preserving as much healthy lung function as possible.

RGCIRC’s thoracic surgical oncology team offers both open surgery and video-assisted thoracoscopic surgery, VATS. VATS is a minimally invasive approach that uses smaller incisions and may help reduce blood loss, post-operative discomfort, and recovery time in suitable patients.

Surgical procedures may include lobectomy, which involves removal of the affected lung lobe; segmentectomy, which may be considered for smaller tumours in selected patients; and mediastinal lymph node dissection or sampling to assess whether the cancer has spread to nearby lymph nodes.

CyberKnife Stereotactic Body Radiation Therapy, SBRT

For some patients with early-stage lung cancer who cannot undergo surgery because of poor lung function, age, or other medical conditions, stereotactic body radiation therapy, SBRT, may be considered.

At RGCIRC, CyberKnife SBRT delivers highly focused radiation to the tumour over a small number of sessions, often three to five, depending on the case. It allows high-dose radiation to be targeted precisely while limiting exposure to surrounding healthy tissue as much as possible.

In appropriately selected patients with early-stage, medically inoperable lung cancer, SBRT can offer excellent local tumour control and may be used with curative intent. This option may be relevant for patients who cannot tolerate thoracic surgery, including some non-smokers who may have good lung function but are not surgical candidates for other health reasons.

Targeted Therapy

Targeted therapy is especially important in advanced non-small cell lung cancer when the tumour carries specific genetic alterations. These alterations are more commonly seen in some non-smokers, particularly those with lung adenocarcinoma.

For example, EGFR-mutant lung cancer may be treated with EGFR tyrosine kinase inhibitors such as osimertinib, depending on the mutation type and treatment setting. ALK-rearranged lung cancer may be treated with ALK inhibitors such as alectinib or lorlatinib. ROS1-positive lung cancer may be treated with drugs such as entrectinib or crizotinib, depending on the patient’s profile and current treatment guidelines.

These oral medicines work by blocking specific cancer-driving pathways. In molecularly selected patients, targeted therapy can produce better response rates, improved symptom control, and better quality of life compared with conventional chemotherapy alone. At RGCIRC, targeted treatment decisions are guided by comprehensive molecular testing.

Immunotherapy

Immunotherapy helps the body’s immune system recognise and attack cancer cells. In lung cancer, checkpoint inhibitors that target PD-1 or PD-L1 may be used in selected patients, either alone or in combination with chemotherapy, depending on the stage, tumour type, PD-L1 expression, molecular test results, and overall treatment plan.

In non-smokers, immunotherapy decisions need careful evaluation because some non-smoker lung cancers may have a lower tumour mutational burden and may respond differently compared with smoking-related lung cancers. PD-L1 testing and other clinical factors help doctors decide whether immunotherapy is suitable.

Chemotherapy

Chemotherapy remains an important treatment for many patients with lung cancer. Platinum-based chemotherapy may be used when targeted therapy is not applicable, when molecular testing does not show an actionable mutation, or when chemotherapy is recommended as part of a combined treatment plan.

Chemotherapy may also be used before surgery, known as neoadjuvant therapy, or after surgery, known as adjuvant therapy, in selected stages of lung cancer. It may also be combined with radiation therapy, immunotherapy, or other treatments depending on the stage and treatment goals.

Palliative and Supportive Care

Palliative care is an important part of lung cancer treatment, especially for patients with advanced disease or symptoms that affect daily life. It is not limited to end-of-life care and should not be seen as giving up treatment.

At RGCIRC, palliative and supportive care may be integrated alongside active cancer treatment to help manage symptoms such as pain, breathlessness, cough, fatigue, poor appetite, anxiety, and treatment-related side effects. Early palliative care can improve comfort, quality of life, treatment tolerance, and emotional support for both patients and families.

Should Non-Smokers Get Screened for Lung Cancer?

Lung cancer screening is different from diagnostic testing. Screening is done in people who do not have symptoms, while diagnostic tests are advised when symptoms such as persistent cough, breathlessness, chest pain, coughing up blood, or repeated chest infections are already present.

Current international lung cancer screening guidelines mainly focus on people with a significant smoking history. For example, the US Preventive Services Task Force recommends annual low-dose CT screening for adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.

For people who have never smoked, there is currently no standard population-wide lung cancer screening recommendation in India. However, some non-smokers may still have a higher-than-average risk because of long-term exposure to air pollution, indoor cooking smoke from solid fuels, second-hand smoke, occupational carcinogens such as asbestos or diesel exhaust, previous lung disease, or a strong family history of lung cancer.

In such cases, the right approach is not to self-prescribe a scan, but to discuss individual risk with a specialist. A doctor can assess the person’s age, symptoms, exposure history, family history, and previous lung conditions before deciding whether low-dose CT or any other test is appropriate.

Most importantly, screening should not replace symptom-based evaluation. If a non-smoker has a persistent or worsening cough, unexplained breathlessness, chest discomfort, blood-stained sputum, hoarseness, unexplained weight loss, or repeated chest infections, they should seek medical evaluation rather than wait for routine screening.

Why Choose RGCIRC for Lung Cancer Treatment?

Lung cancer treatment requires more than one specialist or one test. It needs accurate diagnosis, proper staging, molecular testing, personalised treatment planning, and ongoing supportive care. At RGCIRC, lung cancer care is delivered through a dedicated thoracic oncology programme designed to bring these services together in a coordinated manner. Here’s why patients trust RGCIRC for lung cancer treatment:

Dedicated Thoracic Oncology Team

RGCIRC’s thoracic oncology programme brings together thoracic surgical oncologists, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, and other specialists involved in lung cancer care. This team-based approach is especially important because lung cancer treatment often requires a combination of surgery, radiation therapy, systemic therapy, molecular testing, and supportive care.

Personalised Treatment Planning

Every lung cancer patient is different. The right treatment depends on the cancer stage, tumour type, molecular profile, lung function, overall health, and the patient’s treatment goals. At RGCIRC, treatment planning is personalized rather than one-size-fits-all, with special attention to molecularly driven lung cancers that are often seen in non-smokers.

Multidisciplinary Tumour Board Review

Lung cancer cases at RGCIRC may be reviewed by a multidisciplinary tumour board, where different specialists discuss the diagnosis, staging, and treatment options together. This helps decide the most appropriate treatment sequence, whether the patient needs surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, supportive care, or a combination of treatments.

Advanced Diagnostic and Treatment Support

RGCIRC supports lung cancer care with advanced imaging, biopsy services, bronchoscopy and EBUS, Digital PET-CT, molecular testing, precision radiation therapy, systemic therapy, and thoracic surgical expertise. This allows patients to move from suspicion to diagnosis, staging, and treatment planning in a structured and timely manner.

Care for Both Smokers and Non-Smokers

RGCIRC evaluates and treats lung cancer in both smokers and non-smokers. For non-smokers, this is especially important because lung cancer may be diagnosed late when symptoms are dismissed or when the possibility of cancer is not considered early. The availability of molecular testing and precision treatment planning helps ensure that targetable changes, when present, are not missed.

Recognised Cancer Care Standards

RGCIRC is accredited by NABH and NABL, reflecting recognised standards in hospital care, laboratory services, and diagnostic quality. The institute has also been recognised among Newsweek’s World’s Best Specialised Hospitals in Oncology in 2024 and 2025.

Commitment to Accessible Cancer Care

RGCIRC is a not-for-profit cancer care institution. Through its philanthropy and patient-support initiatives, the institute works to extend financial assistance and subsidised care to eligible patients, helping make specialised cancer treatment more accessible.

Final Words

World Lung Cancer Day 2026 is an opportunity to correct one of the most important misconceptions around lung cancer: that it affects only people who smoke. Smoking remains the strongest known risk factor, but lung cancer can also occur in people who have never smoked, especially when other risk factors such as air pollution, indoor smoke, occupational exposure, previous lung disease, or family history are present.

If you have never smoked but live in a highly polluted city, have long-term exposure to cooking smoke from solid fuels, work in an at-risk occupation, or have a family history of lung cancer, it is worth discussing your risk with a specialist. More importantly, if you have a persistent cough, unexplained breathlessness, chest discomfort, coughing up blood, hoarseness, unexplained weight loss, or repeated chest infections, do not ignore these symptoms simply because you have never smoked.

Early evaluation can make a meaningful difference. When lung cancer is detected at an earlier stage, doctors have more treatment options and a better chance of controlling the disease. Waiting until symptoms become severe can delay diagnosis and make treatment more complex.

To book a consultation at RGCIRC, book online at care.rgcirc.org, or download the RGCI Care app on iOS and Android. You can also call +91-11-4702 2222 for Rohini or +91-11-4582 2222 for Niti Bagh, South Delhi.

OPD hours are Monday to Saturday, 9:00 AM to 5:00 PM. Emergency services are available 24×7 at both campuses.

Frequently Asked Questions

Can non-smokers get lung cancer?

Yes. Lung cancer can occur in people who have never smoked. Smoking remains the strongest known risk factor, but it is not the only one. Air pollution, second-hand smoke, indoor cooking smoke, occupational exposure, radon, previous lung disease, family history, and tumour-related genetic changes can also play a role.

What are the early signs of lung cancer in non-smokers?

Early lung cancer may not cause obvious symptoms. When symptoms do appear, they may include a persistent cough, breathlessness, chest discomfort, hoarseness, coughing up blood or blood-stained sputum, repeated chest infections, unexplained weight loss, or fatigue.

If these symptoms last more than two to three weeks, keep coming back, or worsen over time, they should be medically evaluated.

Why are non-smoker lung cancers different from smoker lung cancers?

Lung cancer in non-smokers is often adenocarcinoma, a common type of non-small cell lung cancer. Non-smokers are also more likely to have certain molecular changes in the tumour, such as EGFR mutations, ALK rearrangements, or ROS1 fusions.

These changes matter because they can help doctors decide whether targeted therapy may be suitable.

Can air pollution cause lung cancer?

Yes. Long-term exposure to air pollution, especially fine particulate matter such as PM2.5, has been linked with a higher risk of lung cancer. It is not the only risk factor, but it is an important one, especially for people living in highly polluted areas.

What is an EGFR mutation in lung cancer?

EGFR is a gene involved in cell growth. In some lung cancers, changes in this gene can make cancer cells grow and multiply. EGFR mutations are more commonly seen in lung adenocarcinoma and are especially relevant in non-smokers.

If an EGFR mutation is found, doctors may consider EGFR-targeted medicines, depending on the patient’s cancer stage, mutation type, and overall treatment plan.

Should non-smokers get screened for lung cancer?

There is currently no standard population-wide lung cancer screening recommendation for people who have never smoked in India. Most formal screening guidelines focus on people with a significant smoking history.

However, non-smokers with multiple risk factors, such as long-term pollution exposure, indoor cooking smoke exposure, occupational exposure, previous lung disease, or a strong family history, can discuss their personal risk with a specialist.

How is lung cancer treated at RGCIRC?

Treatment depends on the cancer stage, tumour type, molecular profile, lung function, overall health, and treatment goals. At RGCIRC, lung cancer care may include surgery, radiation therapy, targeted therapy, immunotherapy, chemotherapy, palliative care, or a combination of these.

Molecular testing is especially important for non-smokers because some tumours may have targetable changes that can guide treatment.

What should I do if I have symptoms but have never smoked?

Do not ignore symptoms just because you have never smoked. Consult a doctor if you have a cough lasting more than two to three weeks, unexplained breathlessness, chest discomfort, blood-stained sputum, hoarseness, unexplained weight loss, or repeated chest infections.

Also mention any risk factors such as pollution exposure, indoor cooking smoke, second-hand smoke, occupational exposure, previous lung disease, or family history of lung cancer. Based on your symptoms, the doctor may advise tests such as a chest X-ray, CT scan, bronchoscopy, biopsy, PET-CT, or molecular testing.

Where can I consult a lung cancer specialist near me in Delhi NCR?

If you are looking for a lung cancer specialist near you in Delhi NCR, you can consult the Thoracic Oncology team at RGCIRC. The team provides evaluation and treatment for lung cancer in both smokers and non-smokers, with access to imaging, biopsy, molecular testing, surgery, radiation therapy, targeted therapy, immunotherapy, and multidisciplinary tumour board review.

RGCIRC has centres at Rohini and Niti Bagh, South Delhi. If symptoms such as persistent cough, breathlessness, chest discomfort, coughing up blood, hoarseness, unexplained weight loss, or repeated chest infections are present, it is better to seek medical evaluation without delay.